Bicara Therapeutics Inc. (BCAX)

NASDAQ: BCAX · Real-Time Price · USD
9.27
-6.39 (-40.80%)
At close: May 23, 2025, 4:00 PM
9.25
-0.02 (-0.22%)
After-hours: May 23, 2025, 7:59 PM EDT
-40.80%
Market Cap 505.55M
Revenue (ttm) n/a
Net Income (ttm) -92.33M
Shares Out 54.54M
EPS (ttm) -3.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,213,472
Open 11.65
Previous Close 15.66
Day's Range 7.80 - 11.70
52-Week Range 7.80 - 28.09
Beta n/a
Analysts Strong Buy
Price Target 29.17 (+214.67%)
Earnings Date May 13, 2025

About BCAX

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2024
Employees 55
Stock Exchange NASDAQ
Ticker Symbol BCAX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BCAX stock is "Strong Buy." The 12-month stock price forecast is $29.17, which is an increase of 214.67% from the latest price.

Price Target
$29.17
(214.67% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity

The recent stock drop in Bicara Therapeutics Inc. is an overreaction, as the full phase 1/1b data—including key OS results—has yet to be released. BCAX interim data for FICERA plus KEYTRUDA in HPV-neg...

10 hours ago - Seeking Alpha

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET...

1 day ago - GlobeNewsWire

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC ...

10 days ago - GlobeNewsWire

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...

25 days ago - GlobeNewsWire

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...

4 weeks ago - GlobeNewsWire

Bicara: Innovative Precision Tumor Targeting

Bicara Therapeutics' lead candidate, ficerafusp alfa, targets EGFR and TGF-beta in tumors, showing promise in hard-to-treat cancers like Head and Neck Squamous Cell Carcinoma. Bicara's financial healt...

4 weeks ago - Seeking Alpha

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting St...

2 months ago - GlobeNewsWire

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...

2 months ago - GlobeNewsWire

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...

3 months ago - GlobeNewsWire

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...

3 months ago - GlobeNewsWire

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...

4 months ago - GlobeNewsWire

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with fu...

6 months ago - GlobeNewsWire

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients w...

6 months ago - GlobeNewsWire

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients ...

8 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand...

Other symbols: GLXGMBXTDTHXCHZBIO
8 months ago - Seeking Alpha

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

Shares of Bicara Therapeutics surged nearly 46% in their market debut on Friday, signaling strong investor interest for the TPG-backed cancer therapy developer.

9 months ago - Reuters

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...

9 months ago - GlobeNewsWire

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

Bicara Therapeutics, a TPG-backed biopharmaceutical company developing a therapy targeting tumors, said on Wednesday it plans to raise up to $265 million through an upsized initial public offering (IP...

9 months ago - Reuters

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, in...

Other symbols: BIOAPMAXPTHLZBIO
9 months ago - Seeking Alpha

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

Bicara Therapeutics said on Friday it is seeking a valuation of up to $828 million in its initial public offering in the United States, as new listings continue to flock the markets.

9 months ago - Reuters

Bicara Therapeutics Plans $200 Million IPO For Head & Neck Cancer Drug

Bicara Therapeutics aims to raise $200 million through an IPO to advance its promising bifunctional antibody treatment for head and neck cancers. The primary drug candidate, ficerafusp alfa, has shown...

9 months ago - Seeking Alpha

Oncology biotech Bicara Therapeutics files for a $200 million IPO

Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, filed on Thursday with the SEC to raise up to $200 million in an initial public offering.

9 months ago - Renaissance Capital

Bicara Therapeutics IPO Registration Document (S-1)

Bicara Therapeutics has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC